Download PDF
CC BY 4.0 · Rev Bras Ortop (Sao Paulo) 2024; 59(04): e599-e606
DOI: 10.1055/s-0044-1788671
Artigo Original
Oncologia

Osteopontin, WNT3A, and ABCB5 Biomarkers Expression in Osteosarcoma Patients

Article in several languages: português | English
Glauco José Pauka Mello 
1   Serviço de Ortopedia e Traumatologia, Hospital Erasto Gaertner, Curitiba, PR, Brasil
,
Cleima Coltri Bittelbrunn 
2   Centro de Ortopedia e Fisioterapia Batel, Curitiba, PR, Brasil
,
Glauco Vinicius Bittelbrunn Pauka Mello 
2   Centro de Ortopedia e Fisioterapia Batel, Curitiba, PR, Brasil
3   Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brasil
,
Fernanda Pinto Garcia 
2   Centro de Ortopedia e Fisioterapia Batel, Curitiba, PR, Brasil
,
Ana Valéria Brunetti Rigolino 
2   Centro de Ortopedia e Fisioterapia Batel, Curitiba, PR, Brasil
,
Pedro Reggiani Anzuatégui 
2   Centro de Ortopedia e Fisioterapia Batel, Curitiba, PR, Brasil
› Author Affiliations Financial Support The authors declare that this study received no financial support from public, commercial, or not-for-profit sources.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective This study aimed to correlate the expression, by immunohistochemistry, of the proteins OPN, ABCB5, and WNT3A from anatomopathological materials obtained from paraffin blocks, slides, or both, from patients with osteosarcoma (OS), analyzing epidemiological characteristics, as well as their presence and influence on the evolution and progression of the disease.

Methods After the initial case selection, we searched for the respective paraffin blocks and took only those with sufficient tumor mass to allow additional sections with no complete loss of biological material. The sarcoma area identification in representative paraffin blocks used multisample blocks (tissue microarray [TMA]) created on a BenchMark ULTRA (Roche Diagnostics Corporation, Indianapolis, IN, USA) instrument. Then, we analyzed the association between the expression of ABCB5, WNT3A, and osteopontin (OPN) markers with the variables age, location, and tissue type (Fisher exact test/Chi-squared test).

Results The average age of the patients was 23 years, and the rate of males and females was the same. We analyzed 40 slides from 28 OS patients seen from 2005 to 2017. Their follow-up time was 80.0 months, and the 5-year survival rate was 46.7%. Most metastases occurred in lung tissue (92.9%). Proteins ABCB5, OPN, and WNT3A did not present statistical significance when compared with age group, neo-adjuvant, adjuvant, or both, chemotherapy, location, survival, or death. Osteopontin was negative in all samples. WNT3A expression occurred in patients who died early.

Conclusion In an immunohistochemical study, ABCB5, OPN, and WNT3A did not have statistical significance. In the parameters analyzed, they did not seem to be a predictive or aggressive factor for OS.

Keywords

biomarkers tumor - immunohistochemistry - osteopontin - osteossarcoma

Work carried out at the Hospital Erasto Gaertner, Curitiba, PR, Brazil.




Publication History

Received: 14 November 2023

Accepted: 29 April 2024

Article published online:
04 September 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • Referências

  • 1 Chen C, Zhao M, Tian A, Zhang X, Yao Z, Ma X. Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget 2015; 6 (19) 17570-17583
    CrossrefPubMedSearch in Google Scholar
  • 2 Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol 2015; 33 (27) 3029-3035
    CrossrefPubMedSearch in Google Scholar
  • 3 Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J 2018; 4: 12
    CrossrefPubMedSearch in Google Scholar
  • 4 Whelan JS, Bielack SS, Marina N. et al; EURAMOS collaborators. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 2015; 26 (02) 407-414
    CrossrefPubMedSearch in Google Scholar
  • 5 Wu Y, Xu L, Yang P. et al. Survival Prediction in High-grade Osteosarcoma Using Radiomics of Diagnostic Computed Tomography. EBioMedicine 2018; 34: 27-34
    CrossrefPubMedSearch in Google Scholar
  • 6 Presti PF, Macedo CRD, Caran EM, Rodrigues AHD, Petrilli AS. Estudo Epidemiológico de Câncer no Adolescente em Centro de Referência. Rev Paul Pediatr 2012; 30 (02) 210-216
    CrossrefSearch in Google Scholar
  • 7 Evola FR, Costarella L, Pavone V. et al. Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Front Pharmacol 2017; 8: 150
    CrossrefPubMedSearch in Google Scholar
  • 8 Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma. Front Oncol 2018; 8 (04) 4
    CrossrefPubMedSearch in Google Scholar
  • 9 Castro JRL, Silva CMTR, Barroso KSN, Lopes JP. Características clínicas e epidemiológicas do paciente adolescente portador de osteossarcoma. Acta Fisiatr 2014; 21 (03) 117-120
    Search in Google Scholar
  • 10 Li Y-S, Deng ZH, Zeng C, Lei GH. Role of osteopontin in osteosarcoma. Med Oncol 2015; 32 (01) 449
    CrossrefPubMedSearch in Google Scholar
  • 11 Calcagno AM, Kim I-W, Wu C-P, Shukla S, Ambudkar SV. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr Drug Deliv 2007; 4 (04) 324-333
    CrossrefPubMedSearch in Google Scholar
  • 12 Moitra K, Scally M, McGee K, Lancaster G, Gold B, Dean M. Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms. PLoS One 2011; 6 (01) e16318
    CrossrefPubMedSearch in Google Scholar
  • 13 Yang M, Li W, Fan D. et al. Expression of ABCB5 gene in hematological malignances and its significance. Leuk Lymphoma 2012; 53 (06) 1211-1215
    CrossrefPubMedSearch in Google Scholar
  • 14 Haydon RC, Deyrup A, Ishikawa A. et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002; 102 (04) 338-342
    CrossrefPubMedSearch in Google Scholar
  • 15 Luo X, Chen J, Song WX. et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 2008; 88 (12) 1264-1277
    CrossrefPubMedSearch in Google Scholar